Altered expression pattern of integrin alphavbeta3 correlates with actin cytoskeleton in primary cultures of human breast cancer
2007

Integrin alphavbeta3 and Actin Cytoskeleton in Breast Cancer Cells

Sample size: 8 publication Evidence: moderate

Author Information

Author(s): Havaki Sophia, Kouloukoussa Mirsini, Amawi Kawther, Drosos Yiannis, Arvanitis Leonidas D, Goutas Nikos, Vlachodimitropoulos Dimitrios, Vassilaros Stamatis D, Katsantoni Eleni Z, Voloudakis-Baltatzis Irene, Aleporou-Marinou Vassiliki, Kittas Christos, Marinos Evangelos

Primary Institution: Laboratory of Histology and Embryology, Medical School, University of Athens

Hypothesis

The study investigates the correlation between integrin alphavbeta3 expression and actin cytoskeleton organization in primary cultures of human breast cancer.

Conclusion

The study developed a model system of primary breast cancer cell cultures that closely resembles the tumor environment, revealing significant changes in integrin alphavbeta3 localization and actin cytoskeleton structure in cancer cells compared to normal cells.

Supporting Evidence

  • Integrin alphavbeta3 was found in different locations in cancer cells compared to normal cells.
  • Cancer cells showed a well-formed actin cytoskeleton with thicker stress fibers.
  • Higher expression of integrin beta3 subunit was observed in breast cancer cells.
  • The study developed a primary culture model that better represents the tumor environment.

Takeaway

Researchers looked at how a protein called integrin alphavbeta3 and the cell's skeleton work together in breast cancer cells, finding that cancer cells behave differently than normal cells.

Methodology

The study used immunofluorescence, immunogold labeling, and Western immunoblotting to analyze integrin alphavbeta3 and actin in primary breast cancer cell cultures.

Limitations

The study is limited by the small sample size and the potential variability in tumor characteristics among the biopsies.

Participant Demographics

The study included biopsies from female patients with infiltrating ductal breast carcinomas, classified as grade I and II.

Digital Object Identifier (DOI)

10.1186/1475-2867-7-16

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication